this quarter I expect to see announcement on major screening programme, and potentially the FDA mandate would be nice.
VHT are brurning a lot of cash. However operating outflows were the same as receipts from customers. Surely this is a good thing!
I would suggest that whist the screening programme has signed up, they may not be fully using the product, therefore company may not be able to recognise the revenue.
I must admit I’m no accounting whiz but based on outflows there will be another need for a credit raise within 12-18 month. I would like to see a strategy to get costs under control. Unless they are trying to be like XRO where the market share is cornered and the barrier to entry too high before they start turning a profit
VHT Price at posting:
$1.76 Sentiment: Buy Disclosure: Held
